HongKong:9966

Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO

* KN026 combined with docetaxel has significant efficacy in the first-line treatment of HER2-positive recurrent or metastatic breast cancer, with mPFS of 26.9 months and 24-month OS rate of 84.2%. * KN026 combined with docetaxel has significant efficacy and good tolerability in the neoadjuvan...

2023-10-24 08:41 3268

Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO

* KN046 showed encouraging efficacy result especially in OS benefit (mOS: 20.2 months) in advanced NSCLC with EGFR sensitivity mutation who progressed after EGFR-TKI(s). * KN046 showed encouraging efficacy result especially in OS benefit (mOS: 13.3months) in advanced NSCLC with EGFR sensitivi...

2023-10-24 08:41 1618

Alphamab Oncology will update the research results of several core pipeline products at the 2023 ESMO Annual Meeting

SUZHOU, China, Aug. 10, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that posters to highlight the company's core pipeline products, PD-L1/CTLA-4 bispecific antibody KN046 and HER2 bispecific antibody KN026, will beannounced at the 2023 European Society for Medical Oncol...

2023-08-10 09:02 2824

Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting

* As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors (other than breast cancer and gastric/gastroesophageal junction cancer) were enrolled, 92.3% of whom had received ≥2L prior systemic therapy. The objective response rate (ORR) was 53.8% with 6.8 mo...

2023-06-06 09:06 2457

IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE

SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for the pivotal trial of the anti-HER2 bispecific antibody KN026 combined with Docetaxel (albumin-binding), i...

2023-05-09 10:00 2613

Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023

SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023). The AACR Annual Meet...

2023-04-17 14:01 2162

Alphamab Oncology Announces the First Patient Dosed in the Phase I Trial of Anti-HER2 bispecific ADC JSKN003

SUZHOU, China, March 16, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed with 2.1mg/kg in a Phase I clinical study (JSKN003-102) of JSKN003, an Anti-HER2 bispecific ADC. ADC drugs have the advantages of highly specific targeting of anti...

2023-03-16 09:58 2449

Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023

SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as  Late-Breaking Research in 114th Annual Meeting of the American Association for Cancer Research (AACR 2023). The res...

2023-03-15 10:06 2658

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022

* As of August 18, 2022,the confirmed ORR for 55 evaluable subjects was 76.4% and DoR was 24.0 months. The disease control rate was 100% in 55 evaluable subjects. * The median follow-up for PFS was 16.6 months. The median PFS was calculated as 25.4 months and yet to become mature. * The med...

2022-12-12 15:51 1923

Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022

* As of Sep 10, 2022, 20 patients completed the surgery and pathological evaluation, tpCR rate were 50%, bpCR rate were 55.0%, and ORR were 100%. * In terms of safety, the incidence Grade ≥3 TEAE were 53.3% (16/30)。The incidence of SAE was 6.7% (2/30) with only one case related to KN026. SUZHO...

2022-12-12 15:00 2156

Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022

* As of August 21, 2022, the ORR from 25 efficacy evaluable TNBC patients was 44.0%, the DCR was 96.0%, and the CBR was 52.0%. * The median follow-up time was 27.93 months. The median PFS was 7.33 months. Among the PD-L1 ≥1% pts, the median PFS was 8.61 months. * The median OS was not mature...

2022-12-12 10:33 2516

Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology

SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at t...

2022-11-22 09:18 3882

Data from KN046 in Patients with metastatic NSCLC who failed first line treatment or prior EGFR-TKIs Presented at ESMO 2022

* 64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s,among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS wa...

2022-09-14 09:11 1999

Alphamab Oncology Presents the updated data from Phase 2 Clinical trial on KN046 Combined with platinum doublet chemotherapy as first-line(1L)treatment for NSCLC at ESMO 2022

* 2-year survival data of this study were presented: KN046 combined with platinum doublet chemotherapy showed promising efficacy and well tolerated safety as first-line(1L)treatment for advanced NSCLC patients * In 87 efficacy evaluable patients, confirmed ORR was 46%. * Median OS in non-squ...

2022-09-14 09:04 1930

Updated Data Presented for KN026 comboKN046 in 1st Line HER2-Positive Gastric/Gastroesophageal Junction Cancer (GC/GEJ)

* As of January 30, 2022,31 patients with HER2-positive unresectable locally advanced or metastatic GC/GEJ, with no prior systemic treatment, were enrolled. 27 patients were evaluable for efficacy. The ORR was 77.8% and DCR was 92.6%. * The phase III pivotal study is planned to confirm the eff...

2022-09-14 09:01 2015

First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer

SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase II clinical study (KN046-209) of PD-L1/CTLA-4 bispecific antibody KN046 plus Axitinib for the first line treatment of advanced Non-Small Cell Lung Cancer (NS...

2022-08-09 11:18 3185

Alphamab Oncology Announced First Patient Dosed in Phase I Trial of PD-L1/OX40 Bispecific Antibody KN052

SUZHOU, China, June 14, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient was dosed in a Phase I clinical study (KN052-CHN-001) of KN052, its proprietary PD-L1/OX40 bispecific antibody, in patients with advanced solid tumors inChina. With the developme...

2022-06-14 08:58 4382

Poster Highlighting Phase II Clinical Study of KN026 for HER2-expressing Advanced GC/GEJ Presented at 2022 ASCO

SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that data from a phase II clinical study of KN026 (HER2 bispecific antibody) monotherapy in patients with previously treated, advance...

2022-06-06 10:49 2687

Research Updates on KN046 Presented at 2022 ASCO

SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (20...

2022-06-06 09:47 2807

First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights

SUZHOU, China, March 30, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year endedDecember 31, 2021 and highlighted recent progress and upcoming milestones. Highlights * First product launch: In November 2021, KN035 (Envafolimab) has receiv...

2022-03-30 10:36 2162
1234